434.82
price down icon3.38%   -15.21
after-market Handel nachbörslich: 432.75 -2.07 -0.48%
loading

Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten

pulisher
03:58 AM

Vertex Pharmaceuticals (VRTX) Faces Downgrade After Q1 Revenue Miss - GuruFocus

03:58 AM
pulisher
03:52 AM

Vertex Pharma extends selloff as Wolfe downgrades after Q1 miss - MSN

03:52 AM
pulisher
03:30 AM

Vertex Pharma stock downgraded at Wolfe (VRTX:NASDAQ) - Seeking Alpha

03:30 AM
pulisher
11:08 AM

Cystic fibrosis Market: Epidemiology, Therapies, Companies, - openPR.com

11:08 AM
pulisher
07:26 AM

VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations - TradingView

07:26 AM
pulisher
06:12 AM

Leerink Partners Downgrades Vertex Pharmaceuticals (BIT:1VRTX) - Nasdaq

06:12 AM
pulisher
06:01 AM

Vertex Pharmaceuticals (VRTX) Sees Target Price Increase to $499 by Barclays | VRTX Stock News - GuruFocus

06:01 AM
pulisher
05:43 AM

Leerink Partners Downgrades Vertex Pharmaceuticals (WBAG:VRTX) - Nasdaq

05:43 AM
pulisher
05:31 AM

Wolfe Research Downgrades Vertex Pharmaceuticals to Peer Perform From Outperform - marketscreener.com

05:31 AM
pulisher
05:15 AM

Vertex Pharmaceuticals (VRTX) Downgraded Amid Revenue Concerns | VRTX Stock News - GuruFocus

05:15 AM
pulisher
04:49 AM

Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip - The Motley Fool

04:49 AM
pulisher
12:56 PM

Vertex stock rating downgraded at Wolfe Research By Investing.com - Investing.com UK

12:56 PM
pulisher
May 06, 2025

Vertex On Track To Significantly Improve Revenue And Earnings By 2030 (NASDAQ:VRTX) - Seeking Alpha

May 06, 2025
pulisher
May 06, 2025

Leerink Partners Downgrades Vertex Pharmaceuticals (LSE:0QZU) - Nasdaq

May 06, 2025
pulisher
May 06, 2025

Vertex Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks

May 06, 2025
pulisher
May 06, 2025

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches - insights.citeline.com

May 06, 2025
pulisher
May 06, 2025

Vertex Pharmaceuticals (VRTX) Analyst Rating Update | VRTX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Goldman Sachs Raises Price Target for Vertex Pharmaceuticals (VRTX) | VRTX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Big-Name Biotech Dives 10% On A Series Of Setbacks - Investor's Business Daily

May 06, 2025
pulisher
May 06, 2025

Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

May 06, 2025
pulisher
May 06, 2025

Why Did Vertex Pharmaceuticals Stock Fall On Tuesday? - Benzinga

May 06, 2025
pulisher
May 06, 2025

Jim Cramer on Vertex (VRTX): “Vertex’s Painkiller Could Be Revolutionary” - Insider Monkey

May 06, 2025
pulisher
May 06, 2025

Tuesday Sector Laggards: Healthcare, Industrial - Nasdaq

May 06, 2025
pulisher
May 06, 2025

Vertex, with new launches gaining steam, boosts revenue forecast despite Trikafta dilemma in Russia - Fierce Pharma

May 06, 2025
pulisher
May 06, 2025

Vertex to manufacture gene therapies in New Hampshire - The Business Journals

May 06, 2025
pulisher
May 06, 2025

Vertex Pharmaceuticals (NasdaqGS:VRTX) Raises Guidance Despite Intangible Asset Impairment Charge - Yahoo Finance

May 06, 2025
pulisher
May 06, 2025

Vertex pauses Moderna-partnered cystic fibrosis trial, takes $379M hit tied to separate program - Fierce Biotech

May 06, 2025
pulisher
May 06, 2025

Vertex Pharmaceuticals (VRTX) Price Target Raised by Morgan Stanley | VRTX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Why Vertex Pharmaceuticals Stock Is Down Sharply - Barron's

May 06, 2025
pulisher
May 06, 2025

Vertex Pharmaceuticals (VRTX) Stock Drops 12% Amid Rising Costs and IP Issues - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Relative Strength Alert For Vertex Pharmaceuticals - Nasdaq

May 06, 2025
pulisher
May 06, 2025

VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened - TradingView

May 06, 2025
pulisher
May 06, 2025

Top Stock Movers Now: Vertex, DoorDash, Constellation Energy, and More - Investopedia

May 06, 2025
pulisher
May 06, 2025

Cantor Fitzgerald maintains Vertex stock Overweight with $535 target By Investing.com - Investing.com UK

May 06, 2025
pulisher
May 06, 2025

Bernstein raises Vertex stock target to $462 on market resilience By Investing.com - Investing.com UK

May 06, 2025
pulisher
May 06, 2025

Stock Movers: Palantir, Vertex Pharmaceuticals, DoorDash - Bloomberg.com

May 06, 2025
pulisher
May 06, 2025

Stifel holds Vertex stock with $194 target post-Q1 results - Investing.com

May 06, 2025
pulisher
May 06, 2025

Why Vertex Pharmaceuticals Stock Is Sinking Today - MSN

May 06, 2025
pulisher
May 06, 2025

Vertex Pharmaceuticals (VRTX) Stock Declines After Earnings Miss - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Vertex Pharmaceuticals Stock Sinks as Costs Soar - Investopedia

May 06, 2025
pulisher
May 06, 2025

2 Pharma Stocks Staging Big Post-Earnings Moves - Schaeffer's Investment Research

May 06, 2025
pulisher
May 06, 2025

Vertex Pharmaceuticals (VRTX) Price Target Raised by JP Morgan | VRTX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Despite Q1 miss, pain drug launch and new CF therapy drive Vertex growth - The Pharma Letter

May 06, 2025
pulisher
May 06, 2025

Vertex Pharmaceuticals (VRTX) Receives Reiterated Overweight Rat - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Vertex Pharmaceuticals (VRTX) Target Price Lowered by Scotiabank Analyst | VRTX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Vertex Pharmaceuticals (VRTX) Receives Reiterated Overweight Rating from Cantor Fitzgerald | VRTX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $621 From $617 - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

Vertex Pharmaceuticals (VRTX) Sees Price Target Increase Amid Adjusted Revenue Guidance | VRTX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Rising Costs Weigh on Vertex Q1 Earnings - Yahoo Finance

May 06, 2025
pulisher
May 06, 2025

Vertex Pharmaceuticals (VRTX) Rating Reiterated at Hold by Needh - GuruFocus

May 06, 2025
pulisher
May 06, 2025

RBC Capital Adjusts Price Target for Vertex Pharmaceuticals (VRT - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Barclays Adjusts Vertex Pharmaceuticals Price Target to $499 From $467, Maintains Equal Weight Rating - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

Vertex Pharmaceuticals (VRTX) Rating Reiterated at Hold by Needham | VRTX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

RBC Capital Adjusts Price Target for Vertex Pharmaceuticals (VRTX) | VRTX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

RBC Raises Price Target on Vertex Pharmaceuticals to $423 From $420, Keeps Sector Perform Rating - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga

May 06, 2025
pulisher
May 06, 2025

This Vertex Pharmaceuticals Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday - Benzinga

May 06, 2025
pulisher
May 06, 2025

Vertex: Improved Outlook Despite First Quarter Miss (Rating Upgrade) (NASDAQ:VRTX) - Seeking Alpha

May 06, 2025
pulisher
May 06, 2025

Scotiabank cuts Vertex stock price target to $442 from $450 By Investing.com - Investing.com UK

May 06, 2025
pulisher
May 06, 2025

Morgan Stanley Lifts Price Target on Vertex Pharmaceuticals to $464 From $462, Keeps Equalweight Rating - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $575 From $550, Maintains Buy Rating - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $464 From $462, Maintains Equalweight Rating - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

JPMorgan Adjusts Price Target on Vertex Pharmaceuticals to $515 From $512, Maintains Overweight Rating - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

Leerink cuts Vertex stock rating, lowers price target to $503 - Investing.com

May 06, 2025
pulisher
May 06, 2025

Vertex Pharmaceuticals (VRTX) Downgraded by Leerink Partners | V - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Vertex Pharmaceuticals (VRTX) Downgraded by Leerink Partners | VRTX Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Vertex Pharmaceuticals: Strong Market Performance and Promising Future Prospects Reinforce Buy Rating - TipRanks

May 06, 2025
pulisher
May 06, 2025

Leerink Partners Downgrades Vertex Pharmaceuticals (BMV:VRTX) - Nasdaq

May 06, 2025
pulisher
May 06, 2025

Vertex Pharmaceuticals (VRTX) Faces Downgrade Amid Uncertain Pro - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Leerink Partners Downgrades Vertex Pharmaceuticals to Market Perform From Outperform, Adjusts Price Target to $503 From $550 - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

Vertex Pharmaceuticals (VRTX) Faces Downgrade Amid Uncertain Prospects | VRTX Stock News - GuruFocus

May 06, 2025
$560.93
price up icon 0.43%
$622.93
price up icon 1.27%
$276.55
price up icon 2.50%
biotechnology ONC
$232.25
price down icon 3.93%
$92.80
price down icon 2.05%
Kapitalisierung:     |  Volumen (24h):